Solid biosciences provides third quarter business update and financial results

– ind submission for sgt-003 for patients with duchenne muscular dystrophy in q4 2023 – – strengthened management team with appointment of dr. gabriel brooks as cmo – – company ends third quarter with approximately $142.9 million in cash and investments; anticipated cash runway through multiple important pipeline milestones and into 2025 – charlestown, mass., nov. 08, 2023 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended september 30, 2023, and provided a business update.
SLDB Ratings Summary
SLDB Quant Ranking